Programs

Home/Programs

Day 1 : Jun 01,2026
Day 1
Agenda Download
Keynote Speakers
Biography:
José Miguel García-Martín Research Scientist at the Spanish National Research Council (CSIC) in the Institute of Micro and Nanotechnology. With a PhD in Physical Sciences (UCM), he was postdoctoral researcher at Paris-Saclay University (France) and a Fulbright Visiting Scholar in the USA twice: at Northeastern University (Boston, MA, 2017) and at the National Institute of Standards and Technology (Boulder, CO, 2025). In 2020, he co-founded the spin-off Nanostine. He has been named Distinguished Lecturer by the IEEE Nanotechnology Council for 2025/2026. In science communication, he co-directed and co-wrote the documentary "40 Años Viendo Átomos", received the 2023 Award from the Royal Spanish Physics Society and the BBVA Foundation for Best Science Communication Contribution, and is co-author of the book "Las nuevas microscopías. Herramientas para la exploración del nanomundo" (2024).

Abstract:
In this talk, I will start explaining how these nanocolumnar thin films are produced by a sustainable method based on physical vapor deposition: glancing angle deposition with magnetron sputtering. I will show that the nanocolumnar morphology results from atomic shadowing effects, along with hyperthermal processes such as atomic diffusion and surface relaxation. Then, I will describe several applications of these nanocolumnar thin films in functional devices in biomedicine. as antibacterial coatings for orthopedic implants, as bioelectrodes for electrical stimulation, as working electrodes in the electrochemical detection of molecules, as templates for molecular sensing by surface enhanced Raman spectroscopy, and as surfaces exhibiting magnetic and plasmonic hyperthermia for in vitro experiments.

Biography:

Prof. Ali Soofastaei is a technology leader specializing in AI-driven digital transformation, data governance, and large-scale analytics. He has led global programs across asset-intensive industries, designing production-grade data platforms, decision-support systems, and MLOps frameworks that improve safety, reliability, and sustainability. Ali holds a PhD in Information Technology (University of Queensland) and an MEng in Systems Engineering (Johns Hopkins University). His work focuses on translating complex, heterogeneous data into actionable, transparent decisions using modern data products, value-driver trees, and explainable machine learning (e.g., SHAP-based analyses). A frequent keynote speaker and author, he partners with executives and multidisciplinary teams to operationalize AI responsibly—linking models to measurable outcomes and robust governance. His current interests include privacy-preserving learning, energy-aware analytics for healthcare facilities, and resilient architectures for real-time clinical and laboratory operations.

Abstract:

Healthcare and bioscience are entering a data-dense era shaped by connected devices, high-throughput laboratories, and digitized clinical workflows. Yet many organizations still struggle to turn heterogeneous data into trustworthy, operational decisions. This talk distills practical lessons from large-scale digital transformation in asset-intensive industries—where safety, reliability, sustainability, and cost discipline must coexist—and maps them to healthcare and bioscience use cases. I will outline a repeatable architecture for predictive and prescriptive analytics that integrates streaming telemetry (wearables, laboratory instruments, building management systems), transactional systems (EHR/LIMS/ERP), and unstructured data (clinical notes, imaging metadata). The approach emphasizes: (1) governed data products with clear ownership and quality SLAs; (2) value-driver trees that translate models into measurable clinical, operational, and sustainability outcomes; (3) robust MLOps for deployment, monitoring, and drift management; and (4) human-centered change management to secure adoption. Methodologically, I will cover forecasting and anomaly detection for patient flow and equipment uptime; classification and ranking for triage and imaging worklists; and reinforcement-learning-style policies for resource scheduling. Model transparency is addressed using explainability techniques (e.g., SHAP summaries at cohort and case levels) and lineage/audit trails to satisfy regulatory and ethical requirements. I will also discuss privacy-preserving patterns (federated/edge training), bias assessment, and governance checkpoints. Illustrative vignettes include: predictive maintenance for critical laboratory and imaging assets; dynamic staffing and theatre scheduling using time-series demand signals; and energy-aware facility control that reduces environmental footprint without compromising patient safety. The session concludes with a pragmatic playbook—maturity assessment, opportunity discovery, minimum viable model, guarded pilot, and scaled rollout—backed by templates and metrics that attendees can adapt to their contexts. The core message is simple: by combining disciplined data governance with explainable, operations-aware AI, healthcare and bioscience organizations can move beyond dashboards to decisions—safely, sustainably, and at scale
.
Speaker Sessions
Biography:

Dr. Tumesh Kumar Sahu is an Assistant Professor at the University Institute of Technology (UIT), Gadchiroli, India. He holds a Ph.D. in Physics with a specialization in graphene and other two-dimensional materials. His academic and research work focuses on advanced nanomaterials, Dirac materials, and functional two-dimensional systems for nanoelectronic and sensing applications.He is also associated with 9N Technology, London, UK, a startup company, where he serves as Lead Scientist working on graphene-based memory devices. Prior to joining academia, he worked as Product and R&D Manager at Multi Nanosense Technology Pvt. Ltd., India. He also served as an R&D Scientist in Turkey for two years, contributing to the design and development of advanced Atomic Force Microscopy systems. Dr. Sahu’s research interests include graphene-based devices, hydrogen sensors, greenhouse gas sensors, and device architectures such as FETs and diode-based applications, with a strong emphasis on translating fundamental materials research into scalable and practical technologies.

Abstract:

Dirac materials are characterized by the emergence of massless quasiparticles in their low-energy excitation spectrum governed by the Dirac Hamiltonian, resulting in linear band dispersion and unusual quantum transport properties. Systems such as graphene, topological insulators, d-wave superconductors, and Weyl and Dirac semimetals have demonstrated the rich physics associated with Dirac fermions. However, none of the Dirac materials identified so far combines Dirac-like electronic behavior with intrinsic metallic character in a purely elemental two-dimensional form.
In this work, we present experimental evidence for the formation of free-standing molybdenene, a two-dimensional material composed exclusively of molybdenum atoms. Using MoS? as a precursor, we induced electric-field-assisted growth under microwave irradiation to engineer the phase transformation and atomic rearrangement required for molybdenene formation. The synthesis results in millimetre-long whiskers grown via a screw-dislocation-driven mechanism. These whiskers consist of weakly bonded layered sheets that can be mechanically exfoliated to obtain ultrathin molybdenene flakes. Electrical characterization reveals clear metallic behavior, with an electrical conductivity of approximately 940 S m?¹ indicating efficient charge transport in the exfoliated layers. The combination of metallic conductivity and two-dimensional morphology distinguishes molybdenene from previously reported Dirac systems and positions it as a promising platform for both fundamental studies and technological applications.
As a proof of principle, we further demonstrate the multifunctionality of molybdenene. The material acts as an effective surface-enhanced Raman spectroscopy (SERS) substrate for molecular sensing, provides a conductive platform suitable for high-resolution electron imaging, and functions as an active material for scanning probe microscope cantilevers.
These findings introduce molybdenene as a new class of metallic two-dimensional Dirac material and open opportunities for its integration into nanoelectronic, sensing, and advanced microscopy technologies.


Biography:
Sahrish Naheed, a master’s student in the School of Materials Science and Engineering at Wuhan University of Technology, China. I completed my Bachelor of Science in Chemistry in Pakistan in 2023 with a CGPA of 3.62. My current research focuses on MOFs, COFs, and POPs for energy applications. I will be presenting virtually at the 9th Edition of the Nanotechnology, Nanomedicine, Material Science & Expo Hybrid Conference, to be held in Bali, Indonesia, and Valencia, Spain.

Abstract:
Due to the intermittent nature of renewable energy sources (solar, wind), there is a need to develop efficient, scalable, and sustainable energy storage systems. Existing energy storage technologies face fundamental challenges, and this study aimed to tackle those challenges by exploring new synthetic routes for novel materials. It focused on enhancing the performance, scalability, and environmental sustainability of energy storage technologies, including lithium-ion batteries, supercapacitors, and hydrogen storage systems. Designing metal-organic frameworks (MOFs), perovskites, and polymer electrolytes via green chemistry principles to minimize the environmental impact of produced materials. The cyclic voltammetric, electrochemical impedance spectroscopic, and long-term cycle stability measurements of electrochemical performance were conducted. Density Functional Theory (DFT) simulations for computational modelling were used to predict material properties and optimize reaction pathways. In these results, MOF-based lithium-ion batteries achieved the best energy density (310 Wh/kg); polymer-based supercapacitors exhibited high power density (2000 W/kg) and cycling stability (94% retention after 1000 cycles). Recently the stability of perovskite-based hydrogen storage systems was improved to 88% of the capacity after 1000 cycles. The results confirmed that using high-performance materials from 21st-century fibers with sustainable synthesis approaches solved key performance and sustainability challenges. It lays a foundation towards stackable and sustainable energy storage systems, which can be used in technological energy grids, electric vehicles, and portable devices.
Abstract:
Atomically precise gold nanoclusters (AuNCs) have emerged as a promising class of nanomaterials bridging the gap between small molecules and nanoparticles, offering unique electronic structures and tunable photophysical properties. Among these, near-infrared (NIR I/II) emitting AuNCs are particularly attractive for biomedical applications due to their ability to enable deep tissue imaging with minimal autofluorescence. However, a fundamental challenge remains in achieving bright, stable NIR emission while maintaining biocompatibility and therapeutic functionality. Here, we present a ligand-centric strategy to engineer NIR-emitting AuNCs by precisely tailoring fluorinated polymeric and small-molecule ligands. Our study demonstrates that ligand chemistry plays a decisive role in governing photoluminescence by modulating ligand-to-metal charge transfer (LMCT) and surface electronic states. Incorporation of fluorinated moieties suppresses non-radiative decay pathways and enhances electronic coupling at the ligand core interface, resulting in significantly improved NIR emission within the biological optical window. This a preserve sub-2 nm cluster size, enabling efficient renal clearance and systemic safety. Beyond optical tuning, the engineered AuNCs function as multifunctional theranostic agents. The fluorinated ligand shell not only stabilizes emission but also contributes to intrinsic pro-apoptotic activity, while further biofunctionalization enables targeted drug delivery. In vitro and in vivo studies in breast cancer models demonstrate efficient tumor accumulation, real-time NIR imaging, and significant tumor suppression with minimal off-target toxicity. This work highlights a broader paradigm in nanomedicine, that surface chemistry dictates function, not just core size. By establishing ligand engineering as a unifying design principle, this study advances AuNCs toward clinically translatable platforms capable of simultaneous imaging, therapy, and disease monitoring, paving the way for next-generation precision oncology.
Biography:
Hari Shanker Sharma, FRSM (UK), is Director of Research (Int. Expt. ECNSIR) and Professor of Neurobiology at Uppsala University, Sweden, affiliated with the Department of Surgical Sciences, Division of Anesthesiology and Intensive Care. Born in Dalmianagar, India (1955), he earned his B.Sc. (Hons) from L.S. College Muzaffarpur in 1973. Dr. Sharma’s pioneering research on the blood-brain barrier and brain edema led to his title of Docent in Neuroanatomy at Uppsala University (2004). His main interests are neuroprotection and neuroregeneration in stress, trauma, and drug abuse. He has received prestigious awards including the Laerdal Foundation Award (2005), NIDA Distinguished Scientist Award (2006–08), Best Investigator Award (2008), and the Dr. Anthony Marmarou Award (2011). With over 30 years of research, he has authored books, edited volumes, and serves on editorial boards of numerous international journals. Dr. Sharma is also a member of renowned academies, including the New York Academy of Sciences.

Abstract:
dl-3-n-butylphthalide (dl-NBP) is one of the potent antioxidant compounds induce profound neuroprotection in stroke and traumatic brain injury. Our previous studies show that dl-NBP reduces brain pathology in Parkinson’s disease (PD) following its nanowired delivery together with mesenchymal stem cells (MSCs) exacerbated by concussive head injury (CHI). CHI alone elevates alpha synuclein (ASNC) in brain or cerebrospinal fluid (CSF) associated with elevated TAR DNA-binding protein 43 (TDP-43). TDP-43 protein is also responsible for the pathologies of PD. Thus, it is likely that exacerbation of brain pathology in PD following brain injury may be thwarted using nanowired delivery of monoclonal antibodies (mAb) to ASNC and/or TDP-43. In this review the co-administration of dl-NBP with MSCs and mAb to ASNC and/or TDP-43 using nanowired delivery in PD and CHI induced brain pathology is discussed based on our own investigations. Our observations show that co-administration of TiO2 nanowired dl-NBP with MSCs and mAb of ASNC or TDP-43 induced superior neuroprotection in CHI induced exacerbation of brain pathology in PD, not reported earlier. 
Biography:
Aruna Sharma (née Bajpai) is a Medical Administrator at Uppsala University Hospital. After graduating in Indian Medicine, she pursued advanced training at Free University Berlin and University Hospital Klinikum Steglitz (1989–1991). She joined the Department of Surgical Sciences in 2004 and has since focused on nanoneurotoxicity, studying the effects of engineered metal nanoparticles and silica dust in brain injury and stress models, supported by EOARD, London. Her research was recognized at the Society for Neuroscience (2011). She is a member of the Swedish Academy of Pharmaceutical Sciences and has served as editor for leading neuroscience journals, contributing significantly to nanoneuroscience.

Abstract:
Blast brain injury (bBI) following explosive detonations in warfare is one of the prominent causes of multidimensional insults to the central nervous and other vital organs injury. Several military personnel suffered from bBI during Middle East conflict at hot environment. The bBI largely occurs due to pressure waves, generation of heat together with release of shrapnel and gun powders explosion with penetrating and/or impact head trauma causing multiple brain damage. As a result, bBI induced secondary injury causes breakdown of the blood-brain barrier (BBB) and edema formation that further results in neuronal, glial and axonal injuries. Previously we reported endocrine imbalance and influence of diabetes on bBI induced brain pathology that was significantly attenuated by nanowired delivery of cerebrolysin in model experiments. Cerebrolysin is a balanced composition of several neurotrophic factors and active peptide fragments is capable of neuroprotection several neurological insults. Exposure to heat stress alone causes BBB damage, edema formation and brain pathology. Thus, it is quite likely that hot environment further exacerbates the consequences of bBI. Thus, novel therapeutic strategies using nanodelivery of stem cell and cerebrolysin may further enhance superior neuroprotection in bBI at hot environment. Our observations are the first to show that combined nanowired delivery of mesenchymal stem cells (MSCs) and cerebrolysin significantly attenuated exacerbation of bBI in hot environment and induced superior neuroprotection, not reported earlier. The possible mechanisms of neuroprotection with MSCs and cerebrolysin in bBI are discussed in the light of current literature.
Biography:
Dr. Mònica Mir received the Degree in Chemistry from University Rovira i Virgili, Spain in 1998. In 2006 she received her PhD in biotechnology in the same University. She realized different predoctoral stages at the Institute of Microelectronic in Demokritos, University of Bath and National Hellenic Research Foundation. From 2007, she held a postdoctoral position in Max Planck Institute for Polymer Research, Germany. Since 2008, she joins the Institute for Bioengineering of Catalonia (IBEC), Spain as Senior CIBER researcher, combined with her teaching as associate professor at the University of Barcelona. Along her carrier she was managing European, National and industrial research projects, supervising PhD ad Master students and collaborating in congresses organization as coordinator and scientific committee. Her main scientific interests are focused on electrochemical biosensor, integrated in lab-on-a-chip and point of care technologies, implantable sensors, and organ-on-a-chip for biomedical applications.

Abstract:
Nanotechnology and nanomedicine is a cutting-edge field that is growing, providing new solutions in different areas. These new technologies in the medical area cover many possibilities for the study, treatment and diagnosis of different diseases in a more efficient and personalized way. A key tool recently developed in biomedical engineering research thanks to this technology are implantable sensors. The development of miniaturized implantable biosensors in the human body has revolutionized the field of medicine in terms of diagnosis, and monitoring of numerous conditions and diseases, such as cardiovascular disorders and metabolic problems. One of the great advances that these sensors have introduced is their ability to monitor clinical data practically in real time, obtaining records of the body's biophysical and biochemical parameters in a continuous way and for extended periods. This talk will present new technologies in implantable sensors specificaally in blood vessels, which allow for continuous monitoring and early detection of diseases. We will show the developments achieved in this area by our research group for different applications, such as monitoring ischemia in fetuses for detection of fetal growth restriction and the detection of biomarkers of heart disease for early diagnosis. Future trends and the advantages and limitations of this technology will be discussed.
Biography:
 
Edda Tobiasch is currently a professor for Genetic Engineering & Cell Culture at the University of Applied Sciences Bonn-Rhein-Sieg (H-BRS). She has studied at the University of Kaiserslautern and made her PhD and a post-doc at the German Cancer Research Center followed by post-doc positions at the University of Heidelberg and the Helmholz Research Center Karlsruhe. She was instructor in the BIDMC at Harvard Medical School, Boston, USA and professor for Virology and Cell Culture at H-BRS. Also, she is a member of the steering committee of the Stem Cell Network NRW and is reviewer for diverse international journals and funding agencies in Germany, Europe and Asia. Edda Tobiasch received several awards and honours for excellent scientific achievements, including an award for innovation. She leads a research group working on mesenchymal, dental, and induced pluripotent stem cells differentiation with focus on Regenerative Medicine. Her focus is currently the development of tissue replacement strategies, mainly for critical size bone defects and yaw bone.

Abstract:

With increasing life expectancy, the clinical demand for regenerative therapies in dentistry—particularly for jawbone reconstruction prior to dental implant placement—is steadily rising.1 Despite significant advances in regenerative medicine, the use of adult stem cells derived from dental tissue waste presents several challenges in clinical translation.2 To identify the most suitable cell source for e.g. alveolar bone regeneration, stem cells from diverse origins have been systematically compared. Furthermore, a novel regenerative strategy has been developed that integrates biomaterial scaffolds, synthetic ligands targeting purinergic receptors—known to promote osteogenesis and angiogenesis—with mesenchymal stem cells.3 Stem cells isolated from cortical and corticocancellous bone chips were characterized by the expression of standard mesenchymal stem cell markers (CD73, CD90, CD105) and subsequently evaluated for their osteogenic differentiation potential.4 These cells were compared with mesenchymal stem cells from other sources and stem cells derived from wisdom teeth. In an in vitro model, a defined set of synthetic and natural ligands for P2 purinergic receptors was employed to enhance both osteogenic and angiogenic responses. Preoperative antibiotic treatment significantly improved the viability of bone chip-derived stem cells. Notably, osteogenic differentiation capacity was independent of the quantity and species of detected microorganisms.4 Intriguingly, stem cells originating from cranial regions—derived from the pharyngeal (brachial) arch exhibited a pronounced pre-commitment toward osteogenic lineage differentiation when compared to stem cells from somite-derived tissues. Based on these findings, a stepwise regenerative approach is proposed: first, ectomesenchymal stem cells are differentiated into osteoblasts on a scaffold system, followed by the application of a specific purinergic receptor ligand or exosomes to stimulate angiogenesis, if required.5 This integrated strategy combining cell-based therapy, bioactive signaling molecules, and biomaterial scaffolds holds significant promise for the future of jawbone reconstruction in clinical dentistry.
Biography:

Dr. Andrew Demian is an Orthodontist with a special interest in clear aligner therapy and dentofacial orthopedics. He graduated from Cairo University, Egypt, in 2017 with an excellent degree and high honors, ranking third in his class. This achievement earned him an observership opportunity at the Medical University of Graz, Austria. He later returned to Egypt to begin his residency in the Orthodontic Department at Cairo University while also serving as a teaching assistant. Dr. Demian completed his Master’s degree focusing on dentofacial orthopedics and further specialized in clear aligners, including directly printed aligner therapy with Graphy.

Abstract:

Background: the aim of the study was to compare the effectiveness of the intra oral technique using Temporary Anchorage Device (TAD) supported class III elastic wear versus the face mask appliance for maxillary protraction which was done following expansion with Alternate Rapid Maxillary Expansion and Constriction (ALT-RAMEC) protocol using Mini-screw assisted rapid maxillary expander (MARME) for treating growing class III patients with maxillary deficiency
Twenty - Four class III growing with Cervical Vertebrae Maturation Stage (CVM) 2-3 with maxillary deficiency treated with the MARME anchored on two palatal mini-screws with a posterior bite plane following an ALT-RAMEC protocol for nine weeks followed by protraction phase for 6 months using intra oral TAD-supported class III elastics in the intervention group and facemask in the control group.
After finishing protraction, Cephalometric measurements were done to assess treatment outcomes.
Results: All patients in the intervention group were successfully treated reaching positive overjet and overbite while three patients in the control group reached only edge to edge relationship because of the patient incompliance. There was significant advancement of A point in both groups with statically insignificant difference between them. There were minimal maxillary dental changes in both groups. However, Mandibular incisors had retroclined slightly more in the control group than in the intervention group but difference was not statistically significant.
Conclusion: The use of MARME following ALT-RAMEC protocol resulted in maxillary advancement even before starting the protraction. The null hypothesis is accepted as when comparing the results of both groups, there was statically insignificant difference between them in correcting such malocclusion. Use of Intraoral device with help of TAD-supproted class III elastic wear is suitable alternative to extraoral conventional facemask for treating growing skeletal class III patients with maxillary deficiency
Biography:

Dr. Padmaja S. MDS in Prosthodontics, is serving as Professor and Head of the Department at Siddhartha Dental College, Karnataka, India. With 17 years of academic teaching experience, she has made significant contributions to the field of Prosthodontics through research, education, and clinical practice. She has authored 46 publications in reputed Scopus and PubMed indexed journals and contributed to two book chapters. Dr. Padmaja is a life member of the Osseointegration Society of India (OSI), Indian Prosthodontic Society (IPS), and Karnataka State Dental Council (KSDC). She has presented papers and delivered master classes at various national and international conferences.

Abstract:

It is the God-given right of every human being to appear human. Face is the patient’s contact with the world and it forms the physical basis for personal recognition. In today’s appearance-conscious society, having a reasonably pleasant appearance has become almost mandatory for social acceptance. Few areas of dentistry offer more challenges to the technical skills or greater satisfaction for the successful rehabilitation of function and esthetics in the patient with gross anatomic defects and deformities of the maxillofacial region. Although remarkable advances in the surgical management of oral and facial defects, but cannot be satisfactorily repaired by plastic surgery alone. Hence, the demand for maxillofacial prosthetic devices for the rehabilitation of patients with congenital or acquired defects has intensified in recent years. This study gives an insight into the latest innovations and improvisations in the field of maxillofacial prosthodontics. Maxillofacial prosthetist normally provides appliances and devices to restore esthetics and function to the patient who cannot be restored to normal appearance or function by means of plastic reconstruction. Biocompatibility is the major prerequisite for a prosthetic material, but the prosthesis must also be easy and inexpensive to fabricate. Over the years, there has been some improvement in facial biomaterials; but still, there exists a clear need for new or improved facial materials in all clinical situations. Maxillofacial prosthetists as a part of anaplastological team can rehabilitate maxillofacial disfigurement with more comfortable, durable, and life-like prosthesis using the latest research, advancements, materials, and techniques in the field to create confidence and a sense of well-being to the patients..
Biography:

Dr. Maite Iglesias Badiola holds a PhD in Molecular Biology from the Autonomous University of Madrid, Spain. She completed postdoctoral research at the National Cancer Institute (NIH, USA), focusing on HPV and cervical cancer progression, and later conducted research at the CSIC in Madrid on epithelial carcinogenesis. Since 2000, she has been a teaching researcher at Universidad Francisco de Vitoria (UFV), where she launched innovative educational programs and the 3Eras Rare Diseases School. She has received two national research recognitions (CNEAI) and published extensively in high-impact international journals. Currently, she is Dean of the Faculty of Experimental Sciences and a Full Professor of Research Methodology, leading a research group in stem cells and regenerative medicine, with a focus on neuronal regeneration in the central nervous system.

Abstract:

Human placental-derived amniotic stromal cells (hAMSCs) have emerged as versatile agents in regenerative medicine due to their immunomodulatory properties, ease of isolation, and secretion of bioactive factors. This work presents two complementary lines of research that demonstrate their therapeutic potential in both neurodegenerative and cardiovascular diseases. In the neurological domain, hAMSCs have been shown to promote regeneration of injured retinal ganglion cells (RGCs) in rats, enhancing axonal growth (19–26 ?m/neuron) and restoring electrophysiological activity under normoxic and hypoxic conditions. Transwell and conditioned medium experiments confirmed that these effects are mediated by paracrine mechanisms involving neurotrophic factors such as BDNF, NGF, and NT-3. Patch clamp recordings validated the functional recovery of regenerated neurons, demonstrating action potential firing. Current investigations focus on placental-derived exosomes, which retain the bioactive properties of the source tissue and offer a promising avenue for personalized medicine. These nanovesicles modulate key cellular processes including inflammation, apoptosis, and regeneration, and are particularly effective in neurodegenerative conditions such as glaucoma. In the cardiovascular context, hAMSCs were evaluated in a murine model of myocardial ischemia/reperfusion (I/R). Intravenous administration of hAMSCs two days post-I/R significantly improved left ventricular ejection fraction (64.5% vs. 50.0% in controls) and reduced myocardial necrosis and fibrosis. Despite minimal direct cellular engraftment, a paracrine mechanism was identified involving extracellular vesicles (EVs) carrying miR-150. This microRNA regulates the MIAT/miR-150/Hoxa4 axis, which is critical for cardioprotection. CRISPR-Cas9 mediated deletion of miR-150 in hAMSCs abolished the therapeutic effect, while administration of purified EVs or lipid nanoparticles containing miR-150 replicated the observed benefits. These findings position hAMSCs as a multimodal therapeutic platform capable of addressing complex pathologies through targeted paracrine signaling and highlight the potential of exosome-based interventions in future regenerative therapies.  
Biography:

Dr. Anand Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson's, Alzheimer's, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. Dr. Srivastava has been associated with leading universities and research institutions of USA. In affiliation with University of California San Diego Medical College (UCSD), University of California Irvine Medical College (UCI), Salk Research Institute, San Diego, Burnham Institute For Medical Research, San Diego, University of California Los Angeles Medical College (UCLA), USA has developed several research collaborations and has an extensive research experience in the field of Embryonic Stem cell which is documented by several publications in revered scientific journals. Furthermore, Dr. Srivastava’s expertise and scientific achievements were recognized by many scientific fellowships and by two consecutive award of highly prestigious and internationally recognized, JISTEC award from Science and Technology Agency, Government of Japan. Also, his research presentation was awarded with the excellent presentation award in the “Meeting of Clinical Chemistry and Medicine, Kyoto, Japan. Based on his extraordinary scientific achievements his biography has been included in “WHO IS WHO IN AMERICA” data bank two times, first in 2005 and second in 2010.

Abstract:

The experimental evidences strongly suggest that embryonic stem (ES) cell lines can be created from human blastocyst-stage embryos and stimulated to develop into practically all types of cells found in the body. Cellular treatments produced from ES cells have attracted fresh interest. The potential utility of ES cells for gene therapy, tissue engineering, and the treatment of a wide spectrum of currently untreatable diseases is simply too vital to ignore; however, further improvements in our understanding of the basic biology of ES cells are required to deliver these forms of therapy in a safe and efficient manner. In this meeting, I'll share my research using ES cells and how they can be used to treat hematopoietic and neurodegenerative disorders. 

Moderator
Biography:
Dr. Cheryl Roche Alexander, DNP, EMBA, is a healthcare strategist, biopharmaceutical executive, and founder of Enlightened Consulting and Dr. Cheryl. Her work bridges biopharma, digital health, patient engagement, population health, value-based care, prevention, and human-centered innovation, with a focus on helping organizations and individuals use technology to improve access, activation, resilience, and outcomes. Across Medical Affairs, Market Access, Commercial, and patient support, she has led and advised initiatives that integrate AI-enabled insights, care coordination, and practical engagement strategies to support earlier identification, treatment, adherence, and patient empowerment. Through Dr. Cheryl, she extends this work into simple self-care systems that help people strengthen physical health, mental clarity, emotional balance, and purpose in an increasingly digital world. As moderator, Cheryl will guide a balanced discussion on how AI, augmented reality, and virtual reality can transform healthcare while requiring thoughtful attention to trust, equity, safety, affordability, and human connection.